Tectonic Therapeutic Inc/$TECX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Tectonic Therapeutic Inc

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Ticker

$TECX
Primary listing

Industry

Biotechnology

Employees

51

TECX Metrics

BasicAdvanced
$417M
-
-$4.72
-
-

Bulls say / Bears say

Tectonic Therapeutic announced positive interim data from its Phase 1b trial for TX45, showing improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in HFpEF. (nasdaq.com)
The company secured approximately $185 million through a private investment in public equity financing, enhancing its financial position to advance clinical programs. (nasdaq.com)
Analysts have given Tectonic Therapeutic a consensus 'Buy' rating, with an average 12-month price target of $72.25, indicating strong growth potential. (slatersentinel.com)
Vanguard Group Inc. reduced its holdings in Tectonic Therapeutic by 18.5% during the fourth quarter, potentially signaling decreased confidence from a major institutional investor. (marketbeat.com)
The company's net loss for Q3 2024 was $17.7 million, reflecting ongoing financial challenges despite a strong cash position. (nasdaq.com)
While positive, the interim data from the TX45 Phase 1b trial is still early-stage, and the success of future phases remains uncertain, posing a risk to the company's pipeline. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TECX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs